rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Amos Bar-Shalev

Director

Company insider

Files Form 4 as: Director and 10% owner, Protalix BioTherapeutics, Inc. (DE).

Every Form 4 they filed

In numbers

Trades disclosed
13
Buys
1
Sells
1
Bought
$14K
Sold
$314
Companies
1
Companies where not an officer
1
First trade
31 Dec 2006
Last trade
3 Sep 2026
Last filed
4 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
PLX Protalix BioTherapeutics, Inc. (DE)Director, 10% owner · Biotechnology · last 3 Sep 20261 buy · 1 sell

Activity over time

1 Nov 2024 – 1 Oct 2026
10Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—17,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—8,500 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—17,000 at $0.00filing
3 Sep 2026filed 4 Sep 2026PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—8,500 at $0.00filing
18 Nov 2025filed 19 Nov 2025PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Sold$314168 at $1.87filing
3 Sep 2025filed 4 Sep 2025PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
3 Sep 2025filed 4 Sep 2025PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—7,500filing
29 Sep 2023filed 3 Oct 2023PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—61,676 at $0.00filing
7 Sep 2022filed 9 Sep 2022PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
20 Jan 2020filed 22 Jan 2020PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
2 Dec 2009filed 9 Dec 2009PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$8,6801,000 at $8.68filing
2 Dec 2009filed 9 Dec 2009PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Bought$5,576680 at $8.20filing
31 Dec 2006filed 5 Jan 2007PLX Protalix BioTherapeutics, Inc. (DE)BiotechnologySEC FORM 4 Code A—6,186,046filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care2

Buys in green, sells in red, by the company’s sector.

Related people

Aharon SchwartzDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year
Gwen A. MelincoffDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year
Yaron NaosSr. VP & COO · Sr. VP & COO at Protalix BioTherapeutics, filing Form 4 there in the last year
Dror BashanPresident and CEO · President and CEO at Protalix BioTherapeutics, filing Form 4 there in the last year
Eliot ForsterDirector · Director at Protalix BioTherapeutics, filing Form 4 there in the last year